SIBO (Small Intestinal Bacterial Overgrowth) Treatment in Dallas, TX

What Is SIBO?

Small intestinal bacterial overgrowth (SIBO) is a condition characterized by an excessive proliferation of bacteria in the small intestine. Under normal physiologic conditions, the small intestine maintains a relatively low bacterial population — typically fewer than 10,000 colony-forming units per milliliter (CFU/mL) — compared to the colon, which harbors trillions of bacteria. This low bacterial count is maintained by several protective mechanisms, including gastric acid secretion (which kills most ingested bacteria), normal small intestinal motility (the migrating motor complex, or MMC, which sweeps residual bacteria and debris through the small bowel during fasting), the ileocecal valve (which prevents retrograde migration of colonic bacteria into the small intestine), intestinal immune defenses (secretory IgA), and biliary and pancreatic secretions.

When one or more of these protective mechanisms is impaired, bacteria from the colon or oropharynx can colonize the small intestine in excessive numbers. These bacteria then ferment dietary carbohydrates that would normally be absorbed in the small bowel, producing hydrogen, methane, and other gases that cause the characteristic symptoms of SIBO: bloating, abdominal distention, flatulence, diarrhea, and abdominal pain. The bacteria also compete with the host for nutrients, consume vitamin B12, deconjugate bile acids (impairing fat absorption), and damage the small intestinal mucosa, potentially leading to malabsorption and nutritional deficiencies.

SIBO has gained increasing clinical recognition as both a standalone condition and as a significant contributor to symptoms in patients diagnosed with irritable bowel syndrome (IBS). Research published in the American Journal of Gastroenterology and other leading journals suggests that SIBO may be present in 30% to 80% of patients meeting diagnostic criteria for IBS, depending on the study population and testing method used.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides evidence-based diagnosis and treatment for SIBO, including hydrogen and methane breath testing, antibiotic therapy, and comprehensive management of underlying causes. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology.

The SIBO-IBS Connection

The relationship between SIBO and IBS is one of the most actively studied and clinically relevant topics in functional gastroenterology. Both conditions share remarkably similar symptom profiles — bloating, abdominal pain, altered bowel habits, and excessive gas — and distinguishing between them based on symptoms alone is often impossible.

Several lines of evidence support a meaningful connection between SIBO and IBS. Studies using breath testing have shown significantly higher rates of positive results in IBS patients compared to healthy controls. The antibiotic rifaximin, which targets small intestinal bacteria, has been shown in randomized controlled trials to improve symptoms in IBS-D (diarrhea-predominant IBS), leading to its FDA approval for IBS-D. Furthermore, many patients initially diagnosed with IBS experience substantial or complete symptom resolution after successful SIBO treatment, suggesting that bacterial overgrowth was the underlying or contributing cause of their symptoms.

The ACG acknowledges this overlap and notes that breath testing may be considered in IBS patients with bloating and diarrhea who have risk factors for SIBO. At Texas Gut Health, Dr. John takes a thorough approach to evaluating patients with IBS-like symptoms, including assessment for SIBO when clinically appropriate, to ensure that a treatable cause of symptoms is not overlooked.

Symptoms of SIBO

The symptoms of SIBO can range from mild to debilitating and often overlap significantly with those of IBS and other functional gastrointestinal disorders. Symptoms result from bacterial fermentation of carbohydrates, competition for nutrients, bile acid deconjugation, and mucosal inflammation.

Gastrointestinal Symptoms

• Bloating and abdominal distention — Bloating is the most common and often the most troublesome symptom of SIBO. It results from excessive gas production as bacteria ferment carbohydrates in the small intestine. Patients often report that bloating worsens progressively throughout the day and after meals.
• Excessive gas and flatulence — Increased production of hydrogen and methane gas by overgrown bacteria leads to frequent belching and flatulence.
• Diarrhea — Diarrhea is the predominant bowel pattern in hydrogen-producing SIBO. It occurs because bacterial deconjugation of bile acids impairs fat absorption, bacterial metabolites stimulate colonic secretion, and mucosal damage may reduce absorptive surface area. Stools may be loose, watery, and frequent.
• Constipation — Methane-predominant overgrowth (now termed intestinal methanogen overgrowth, or IMO) is associated with constipation rather than diarrhea. Methane gas produced by archaea (primarily Methanobrevibacter smithii) slows intestinal transit by acting directly on smooth muscle, leading to infrequent, hard stools.
• Abdominal pain and cramping — Diffuse or localized abdominal pain, often in the periumbilical region, is common and may be related to gas distention, altered motility, and visceral hypersensitivity.
• Nausea — Nausea may occur, particularly in patients with severe overgrowth or concurrent gastroparesis.

Systemic and Nutritional Symptoms

• Fatigue — Fatigue is frequently reported by SIBO patients and may result from malabsorption of nutrients, chronic inflammation, and the systemic effects of bacterial metabolites.
• Vitamin B12 deficiency — Bacteria in the small intestine consume vitamin B12 before it can be absorbed. B12 deficiency can cause fatigue, numbness and tingling in the hands and feet (peripheral neuropathy), cognitive difficulties, and macrocytic anemia.
• Iron deficiency — Chronic mucosal inflammation and impaired absorption can lead to iron deficiency and anemia.
• Fat-soluble vitamin deficiencies — Bacterial deconjugation of bile acids impairs fat absorption, potentially leading to deficiencies of vitamins A, D, E, and K. Consequences may include bone loss (vitamin D), easy bruising (vitamin K), and impaired night vision (vitamin A).
• Unintentional weight loss — In severe or prolonged SIBO, malabsorption of macronutrients (fats, carbohydrates, and proteins) can lead to weight loss and malnutrition.

Causes & Risk Factors

SIBO develops when the body's normal defense mechanisms against small intestinal bacterial colonization are compromised. Understanding the underlying cause is essential for effective treatment and prevention of recurrence.

Impaired Small Intestinal Motility

• Diabetes mellitus — Diabetic autonomic neuropathy can impair the migrating motor complex (MMC), the coordinated pattern of small intestinal contractions that sweeps bacteria and debris distally during fasting periods. SIBO prevalence is estimated at 40% to 50% in patients with long-standing diabetes.
• Scleroderma and connective tissue disorders — Scleroderma can involve the smooth muscle of the gastrointestinal tract, severely impairing motility and predisposing to significant SIBO.
• Opioid use — Chronic opioid use slows intestinal motility and suppresses the MMC, creating a favorable environment for bacterial overgrowth.
• Gastroparesis — Delayed gastric emptying and associated dysmotility increase the risk of SIBO.
• Hypothyroidism — Untreated hypothyroidism can slow intestinal motility and has been associated with increased SIBO risk.

Reduced Gastric Acid

• Chronic PPI use — Proton pump inhibitors potently suppress gastric acid production, removing one of the body's primary barriers against bacterial overgrowth. Meta-analyses have demonstrated a significant association between long-term PPI use and SIBO.
• Atrophic gastritis — Chronic inflammation of the stomach lining (often caused by H. pylori or autoimmune gastritis) can reduce acid-producing capacity and increase SIBO risk.
• Prior gastric surgery — Surgical procedures that reduce acid production or alter gastric anatomy (such as vagotomy or partial gastrectomy) predispose to SIBO.

Structural and Anatomical Factors

• Surgical blind loops — Prior abdominal surgery can create blind loops or pouches where bacteria accumulate and proliferate (the classic "blind loop syndrome").
• Small bowel strictures and adhesions — Strictures from Crohn's disease, radiation enteritis, or surgical adhesions can cause stasis and promote bacterial overgrowth.
• Ileocecal valve dysfunction or resection — Removal or incompetence of the ileocecal valve allows retrograde migration of colonic bacteria into the small intestine.
• Small bowel diverticula — Diverticula in the small intestine (jejunal diverticulosis) can harbor stagnant bacteria.

Other Risk Factors

• Immune deficiency — Conditions that impair intestinal immune defenses (such as IgA deficiency, HIV, or immunosuppressive therapy) can increase susceptibility to SIBO.
• Chronic kidney disease — Uremia-related dysmotility and other factors increase SIBO prevalence in patients with chronic kidney disease.
• Chronic pancreatitis — Exocrine pancreatic insufficiency and associated dysmotility can predispose to SIBO.
• Older age — Age-related decline in gastric acid production, intestinal motility, and immune function may contribute to the higher prevalence of SIBO in elderly populations.

How SIBO Is Diagnosed

Diagnosing SIBO can be challenging because its symptoms overlap with many other gastrointestinal conditions. Several diagnostic approaches are available, each with its own strengths and limitations.

Hydrogen and Methane Breath Testing

Breath testing is the most widely used and practical diagnostic test for SIBO. The test is non-invasive, inexpensive, and can be performed in the office or at home. The principle is straightforward: after an overnight fast and a preparatory diet, the patient ingests a sugar substrate (either lactulose or glucose), and breath samples are collected at regular intervals (typically every 15 to 20 minutes for 2 to 3 hours) to measure exhaled hydrogen and methane levels.

• Lactulose breath test — Lactulose is a synthetic sugar that is not absorbed in the small intestine and reaches the colon intact. In SIBO, an early peak in hydrogen or methane occurs as bacteria in the small intestine ferment the lactulose before it reaches the colon, followed by a later colonic peak. The lactulose breath test can detect SIBO throughout the entire small intestine but has lower specificity (higher false-positive rate) than the glucose breath test.
• Glucose breath test — Glucose is rapidly absorbed in the proximal small intestine. A rise in hydrogen or methane after glucose ingestion indicates bacterial fermentation in the proximal small bowel. The glucose breath test has higher specificity but may miss overgrowth limited to the distal small intestine, as glucose is fully absorbed before reaching those areas.

The 2017 North American Consensus defines a positive breath test as a rise in hydrogen of 20 or more parts per million (ppm) above baseline within 90 minutes, or a methane level of 10 or more ppm at any point during the test. Elevated methane suggests intestinal methanogen overgrowth (IMO), which has distinct treatment implications.

Small Bowel Aspirate and Culture

Direct aspiration and quantitative culture of jejunal fluid obtained during upper endoscopy is considered the gold standard for diagnosing SIBO. A bacterial count of 10,000 or more CFU/mL (revised from the older threshold of 100,000 CFU/mL) is considered diagnostic. However, this method is invasive, expensive, can be subject to contamination, and may not detect distal small bowel overgrowth. For these reasons, it is used infrequently in clinical practice and is generally reserved for cases where breath testing is inconclusive or unavailable.

Additional Evaluation

When SIBO is diagnosed or suspected, Dr. John performs a thorough evaluation to identify underlying causes and contributing factors. This may include assessment of GI motility, review of medications (especially PPIs, opioids, and prokinetics), evaluation for structural abnormalities (CT enterography, small bowel follow-through, or capsule endoscopy), testing for conditions that predispose to SIBO (diabetes, hypothyroidism, celiac disease), and nutritional assessment (B12, folate, iron, fat-soluble vitamins, albumin).

Treatment Options

Effective SIBO management requires a multi-pronged approach: eradicating the overgrown bacteria with antibiotics, addressing the underlying predisposing condition, implementing dietary strategies to reduce symptoms and recurrence, and, when appropriate, using prokinetic agents to restore normal motility.

Antibiotic Therapy

Antibiotic therapy is the primary treatment for SIBO. The choice of antibiotic depends on the type of overgrowth (hydrogen-predominant vs. methane-predominant) and the patient's clinical profile.

• Rifaximin (Xifaxan) — Rifaximin is a non-absorbable antibiotic that acts locally in the gut and is the most studied and commonly prescribed antibiotic for SIBO. It is generally well tolerated with minimal systemic side effects. Rifaximin is FDA-approved for IBS-D and is widely used off-label for hydrogen-predominant SIBO. A typical course is 550 mg three times daily for 14 days. Response rates of 50% to 70% have been reported.
• Rifaximin plus neomycin or metronidazole (for methane-predominant SIBO/IMO) — Methane-producing archaea are not effectively targeted by rifaximin alone. Combination therapy with rifaximin plus neomycin (500 mg twice daily) or metronidazole (250 mg three times daily) for 14 days is recommended for methane-predominant overgrowth and has shown superior efficacy compared to rifaximin monotherapy for reducing methane levels.
• Other antibiotics — In cases of treatment failure or recurrence, alternative or rotational antibiotic strategies may include ciprofloxacin, amoxicillin-clavulanate, doxycycline, or trimethoprim-sulfamethoxazole, depending on the clinical scenario.

Dietary Modifications

Dietary therapy is used as an adjunct to antibiotic treatment and as a maintenance strategy to reduce symptoms and recurrence risk.

• Low-FODMAP diet — The low-FODMAP diet restricts fermentable carbohydrates (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) that serve as substrates for bacterial fermentation. By reducing the amount of fermentable material reaching the small intestine, this diet can significantly decrease gas production, bloating, and diarrhea. The low-FODMAP diet has strong evidence supporting its efficacy in IBS and is increasingly used in SIBO management.
• Specific Carbohydrate Diet (SCD) and SIBO-specific diet — These diets further restrict complex carbohydrates and starches to "starve" overgrown bacteria. While clinical evidence is more limited than for the low-FODMAP diet, many patients report symptom improvement with these approaches.
• Meal spacing — Spacing meals at least 4 to 5 hours apart and avoiding snacking allows the migrating motor complex (MMC) to activate between meals. The MMC only occurs during fasting and is responsible for sweeping bacteria and debris through the small intestine. Frequent eating suppresses the MMC and may promote bacterial overgrowth.

Prokinetic Agents

Because impaired small intestinal motility is a common predisposing factor for SIBO, prokinetic agents are used to restore normal motility and prevent recurrence after successful antibiotic treatment. Options include:

• Low-dose erythromycin — At sub-antibiotic doses (50 to 100 mg at bedtime), erythromycin acts as a motilin receptor agonist, stimulating the MMC and promoting small bowel clearance during the overnight fasting period.
• Prucalopride — A selective serotonin 5-HT4 receptor agonist that promotes intestinal motility and may be particularly useful in patients with constipation-predominant symptoms.
• Low-dose naltrexone (LDN) — Some evidence suggests that low-dose naltrexone may improve gut motility and reduce inflammation, though data specifically for SIBO prevention is limited.

Treating the Underlying Cause

Addressing the underlying predisposing condition is crucial for preventing SIBO recurrence. This may include optimizing diabetes management, reducing or discontinuing unnecessary PPI therapy, tapering opioid medications when possible, evaluating and treating structural abnormalities, managing hypothyroidism, and treating celiac disease or other mucosal conditions.

Living With SIBO

SIBO is a manageable condition, but it can be a recurring one. Understanding this reality and working closely with your gastroenterologist to develop a comprehensive long-term plan are essential for maintaining symptom control and quality of life. Many patients find that a combination of targeted antibiotic therapy, dietary adjustments, and attention to underlying risk factors allows them to achieve sustained relief from symptoms.

Recurrence is one of the most challenging aspects of SIBO. Studies suggest that SIBO recurs in approximately 40% to 50% of patients within the first year after successful antibiotic treatment, particularly when the underlying predisposing condition has not been adequately addressed. Prokinetic therapy taken at bedtime can help stimulate the migrating motor complex during overnight fasting and is an important maintenance strategy for reducing recurrence. Meal spacing — allowing 4 to 5 hours between meals and avoiding late-night snacking — also supports natural gut motility.

Dietary management plays a key role in long-term SIBO care. While strict elimination diets are not intended to be followed indefinitely, learning to identify your personal trigger foods and making sustainable adjustments can significantly reduce symptom burden. Working with a registered dietitian experienced in GI nutrition can be valuable, particularly for patients concerned about maintaining adequate nutritional intake while following a modified diet. Monitoring for nutritional deficiencies — including vitamin B12, iron, folate, and fat-soluble vitamins — is important, especially in patients with recurrent or long-standing SIBO.

At Texas Gut Health, Dr. John provides ongoing follow-up care for patients with SIBO throughout the Dallas-Fort Worth metroplex, including Sachse, Plano, Garland, Richardson, Murphy, and surrounding communities. If you are experiencing persistent or recurrent GI symptoms, contact us at (214) 624-6596 to schedule a consultation.

Frequently Asked Questions